Talphera (TLPH) Cash from Financing Activities (2010 - 2026)
Talphera's (TLPH) quarterly Cash from Financing Activities came in at $4.0 million in Q1 2026, up 80960.0% year-on-year from N/an in Q1 2025, and up 188.17% quarter-over-quarter from $1.4 million in Q4 2025.
Talphera (TLPH) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Talphera's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $4.0 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 80960.0% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $26.8 million, a 107052.0% increase from a year earlier, with the FY2025 full-year figure at $22.7 million, up 88.81% from the prior year.
- Cash from Financing Activities rose to $4.0 million in Q1 2026 per TLPH's latest filing, from $1.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $17.0 million in Q3 2025 and bottomed at -$3.3 million in Q2 2023.
- The 5-year median for Cash from Financing Activities is $30000.0 (2024), against an average of $2.8 million.
- Across the five-year window, Cash from Financing Activities plunged 106.09% in 2022 and surged 80960.0% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at $5.3 million in 2022, then sank by 101.28% to -$68000.0 in 2023, then soared by 144.12% to $30000.0 in 2024, then jumped by 4576.67% to $1.4 million in 2025, then surged by 188.17% to $4.0 million in 2026.
- Per Business Quant, the three latest TLPH Cash from Financing Activities figures stand at $4.0 million (Q1 2026), $1.4 million (Q4 2025), and $17.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | 4.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.04 Mn |
| Mar 31, 2026 | 4.04 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 16.99 Mn |
| Sep 30, 2025 | 16.99 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Mar 31, 2025 | -5,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Sep 30, 2024 | 30,000.00 |
| Sep 30, 2024 | 30,000.00 |
| Mar 31, 2024 | 12.01 Mn |
| Mar 31, 2024 | 12.01 Mn |
| Dec 31, 2023 | -68,000.00 |
| Dec 31, 2023 | -68,000.00 |
| Sep 30, 2023 | 8.94 Mn |
| Sep 30, 2023 | 8.94 Mn |
| Jun 30, 2023 | -3.33 Mn |
| Jun 30, 2023 | -3.33 Mn |